Initially designed to treat type 2 diabetes, GLP-1 drugs are now being explored for a range of metabolic conditions. Evidence suggests they are effective in obesity management, cardiovascular protection, and liver function improvement. Their ability to simultaneously manage blood sugar and body weight makes them an attractive treatment option for multiple patient populations.

Emerging therapies, including dual agonists targeting GLP-1 and GIP receptors, show promising results in clinical trials. These developments highlight the versatility and future potential of the GLP-1 drug class. Healthcare professionals are increasingly incorporating GLP-1 drugs into broader treatment strategies. For further details on market trends and future growth, see the GLP-1 Drug Market.